Lineage Cell Therapeutics Inc (LCTX)

[Paulness]

NEWS -- Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference

CARLSBAD, Calif., January 04, 2022--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer will be presenting at the H.C. Wainwright Bioconnect Virtual Conference (https://hcwevents.com/bioconnect/). The corporate presentation will be available to investors on demand, starting on January 10, 2022 at 7:00am ET on the Events and Presentations section of Lineage’s website (https://investor.lineagecell.com/events-and-presentations/upcoming-events).

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic ("off-the-shelf") product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, which is now being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit https://www.lineagecell.com or follow the Company on Twitter @LineageCell.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005219/en/

Contacts

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(mailto://[e-mail])
[phone]

Solebury Trout IR
Mike Biega
(mailto://[e-mail])
[phone]

Russo Partners – Media Relations
Nic Johnson or David Schull
mailto://[e-mail]
mailto://[e-mail]
[phone]